Could This Treatment for Ulcerative Colitis and Crohn’s Disease Get Approved in Europe?
source: shutterstock.com

Could This Treatment for Ulcerative Colitis and Crohn’s Disease Get Approved in Europe?

According to reporting from News-Medical.net, Janssen-Cilag International NV recently announced that it had applied for European Medicines Agency (EMA) approval of its drug guselkumab (marketed as TREMFYA) in an expansion…

Continue Reading Could This Treatment for Ulcerative Colitis and Crohn’s Disease Get Approved in Europe?
Phase 3 Program on Cobitolimod for UC Discontinued After Inability to Meet Primary Endpoint
slon_dot_pics / Pixabay

Phase 3 Program on Cobitolimod for UC Discontinued After Inability to Meet Primary Endpoint

  The risk of developing an inflammatory bowel disease (IBD) such as Crohn's disease or ulcerative colitis (UC) has been slowly but steadily increasing over time, with an estimated 0.8%…

Continue Reading Phase 3 Program on Cobitolimod for UC Discontinued After Inability to Meet Primary Endpoint
Which Treatment Leads to Better UC Clinical Responses: Upadacitinib or Ustekinumab?
source: pixabay.com

Which Treatment Leads to Better UC Clinical Responses: Upadacitinib or Ustekinumab?

During the ACG Annual Scientific Meeting, which took place this year from October 20 through 25, one presenter shared insights into a multicenter retrospective cohort study which explored the efficacy…

Continue Reading Which Treatment Leads to Better UC Clinical Responses: Upadacitinib or Ustekinumab?
Positive Topline Data Available on ALTB-268 for Ulcerative Colitis 
https://pixabay.com/en/anatomical-anatomy-body-gut-health-2261006/

Positive Topline Data Available on ALTB-268 for Ulcerative Colitis 

  In a Phase 1 clinical study, researchers wanted to understand whether ALTB-268, developed by clinical-stage biotechnology company AltruBio Inc., could be effective in treating ulcerative colitis. The study first…

Continue Reading Positive Topline Data Available on ALTB-268 for Ulcerative Colitis 

Generic Budesonide Rectal Foam Now Approved for Mild-to-Moderate Ulcerative Colitis

In the past, budesonide has been used in a number of therapeutic indications, such as to reduce proteinuria in IgA nephropathy or digestive tract inflammation in those with Crohn's disease.…

Continue Reading Generic Budesonide Rectal Foam Now Approved for Mild-to-Moderate Ulcerative Colitis
Rare Community Profiles: This Rare Family is Managing CVID, MS, UC, and Double Cortex Syndrome: Here’s How You Can Help
source: shutterstock.com

Rare Community Profiles: This Rare Family is Managing CVID, MS, UC, and Double Cortex Syndrome: Here’s How You Can Help

Rare Community Profiles   Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families,…

Continue Reading Rare Community Profiles: This Rare Family is Managing CVID, MS, UC, and Double Cortex Syndrome: Here’s How You Can Help
Cyclosporine Contributes to Long-Term Treatment Efficacy in Ulcerative Colitis (UC)
Photo by Paweł Czerwiński on Unsplash

Cyclosporine Contributes to Long-Term Treatment Efficacy in Ulcerative Colitis (UC)

Certain patients with ulcerative colitis (UC) do not respond well to steroid treatment. These patients are considered to have steroid-refractory acute severe ulcerative colitis, or ASUC. Other therapeutic options, such…

Continue Reading Cyclosporine Contributes to Long-Term Treatment Efficacy in Ulcerative Colitis (UC)

ICYMI: Patients with a Certain Genotype Are More Likely to Discontinue Imuran Due to Toxicity

  Dr. Cecilia Chung and associates at the Vanderbilt University’s Medical Center conducted a study published recently in MedPage Today. Results showed that patients who had inflammatory disorders, as well…

Continue Reading ICYMI: Patients with a Certain Genotype Are More Likely to Discontinue Imuran Due to Toxicity
Jyseleca for Ulcerative Colitis Approved in Scotland for NHS Coverage
Source: https://unsplash.com/photos/ZHys6xN7sUE

Jyseleca for Ulcerative Colitis Approved in Scotland for NHS Coverage

  What happens when you treat your condition, but the medication isn’t effective? Sometimes, other approved medications are beneficial for patient use, but other times, there are no approved medications.…

Continue Reading Jyseleca for Ulcerative Colitis Approved in Scotland for NHS Coverage
Phase 2 PRA023 Trial for UC Begins
source: pixabay.com

Phase 2 PRA023 Trial for UC Begins

Clinical trials are important research tools to help understand the safety, efficacy, and tolerability of potential treatments. According to a news release from July 19, 2021, biotechnology company Prometheus Biosciences,…

Continue Reading Phase 2 PRA023 Trial for UC Begins